FZD7 and ovarian carcinoma: As in our study, a dysregulated Wnt pathway and, more specifically, overexpression of FZD10 and FZD7 (another member of the Wnt cell-surface receptor family) were related to worse prognosis, so this FZD10 blocking antibody may have clinical potential by inhibiting the autocrine Wnt signalling pathway in ovarian cancer.